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MaTransthyretin amyloidosis is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy.
It occurs in both a mutant form (with autosomal dominant inheritance) and a wild-type form (with predominant cardiac
involvement). This article guides clinicians as to when the disease should be suspected, describes the appropriate diagnostic
evaluation for those with known or suspected amyloidosis, and reviews the interventions currently available for affected
patients. (J Am Coll Cardiol 2015;66:2451–66) © 2015 by the American College of Cardiology Foundation.I n 1858, Rudolf Virchow described the reaction oftissue deposits with iodine and sulfuric acid.This reaction was known as a marker for starch
in plants; thus, Virchow referred to the deposits as
starch-like or “amyloid.” Recognition that these de-
posits stained with Congo red occurred in 1922, and
the apple-green birefringence was discovered in
1927 in the brain of a patient with Alzheimer’s disease
(1). Deposits of transthyretin (TTR), a tetrameric pro-
tein rich in b strands that is highly conserved and
present in all human serum, can cause amyloidosis.
TTR’s physiological function includes transportation
of thyroxine and retinol-binding protein; the name
transthyretin was coined from transports thyroxine
and retinol.
TTR is synthesized primarily by the liver, with <5%
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in behavior, cognition, nerve regeneration, and
axonal growth (2). TTR has an innate ability to
aggregate into insoluble amyloid ﬁbers. Transient
accumulation of TTR oligomers, composed of 6 to 10
monomers, may cause cell toxicity or tissue damage.
Single point mutations can increase the likelihood of
TTR misfolding into an insoluble b-pleated sheet,
which deposits in the heart, nerves, and other tissues,
causing familial amyloid cardiomyopathy, familial
amyloid polyneuropathy (FAP), and leptomeningeal
amyloidosis (3,4). Table 1 provides the most common
mutations recently reported from a single U.S. center.
More than 80 TTR mutations have been described,
including the nonpathogenic G6S mutation found in
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TABLE
With Sym
TTR Muta
T60A
V30M
V122I
S77T
L111M
E89Q
All other
Values are
TTR ¼ t
ABBR EV I A T I ON S
AND ACRONYMS
AL = immunoglobulin light
chain
ATTR = transthyretin
amyloidosis
CMR = cardiac magnetic
resonance
DPD = diphosphono-
propanodicarboxylic acid
FAP = familial amyloid
polyneuropathy
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
siRNA = small interfering
ribonucleic acid
TTR = transthyretin
wt = wild type
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2452is the most frequent reported globally. Three
major clusters in Portugal, Sweden, and Japan
have been described. The Portuguese and
Japanese appear to have a single founder in
the 15th century (brought from Portugal to
Japan by explorers) (5,6). The V30M mutation
seems to have appeared later in Sweden than
in Portugal and Japan (7). The largest pop-
ulations of mutant TTR, V30M (p.V50M), are
in endemic areas of Japan, Sweden, and
Portugal, with large cohorts in Brazil (8). The
T60A mutation originated in northwest
Ireland and came to the United States, where
it was termed Appalachian amyloidosis. The
V122I founder likely originated in West Africa,
as indicated by V122I TTR expression in the
Caribbean islands.
Wild-type (wt) TTR can also misfold into
the amyloid conﬁguration. Previously termed senile
cardiac amyloidosis and subsequently as senile sys-
temic amyloidosis, wt TTR amyloidosis will be called
wt transthyretin amyloidosis (ATTR) in this paper. Wt
ATTR is sporadic, with no known biomarkers for its
diagnosis. Deposition of the wt protein occurs almost
exclusively (90%) in men >60 years of age.
CLINICAL CHARACTERISTICS
OF CARDIAC AMYLOIDOSIS
Amyloid inﬁltration results in poor diastolic relaxa-
tion (poor ﬁlling, with low end-diastolic volume).
Doppler measures of inﬂow velocity can detect left
ventricular diastolic ﬁlling abnormalities, and
Doppler diastolic ﬁlling variables are prognostic in
cardiac amyloidosis. Shortened deceleration time and
an increased early diastolic ﬁlling velocity to atrial
ﬁlling velocity ratio are stronger predictors of cardiac
death (9). Amyloid cardiomyopathy should be sus-
pected in any patient who presents with heart
failure and preserved ejection fraction. Findings of1 Most Common TTR Mutations Identiﬁed in Patients
ptomatic Amyloidosis
tion
Mayo
Clinic
TTR Amyloidosis
Outcomes Survey
26.0 1.7
16.0 73.3
11.0 4.4
6.0 1.6
0.0 1.9
0.0 2.1
s 41.0 16.7
%. Data from Coelho et al. (21) and Swiecicki et al. (22).
ransthyretin.right-sided heart failure predominate, including
lower-extremity edema, hepatomegaly, ascites, and
elevated jugular pressure. Right ventricular dilation
is linked to more severe cardiac involvement and
short survival (median 4 months) (10). A study of 74
patients with biopsy-proven immunoglobulin light
chain (AL) amyloidosis showed an association of right
ventricular dysfunction with more severe involve-
ment of the left ventricle, higher plasma levels of
N-terminal pro–B-type natriuretic peptide (NT-proBNP),
and poor prognosis (11).
Using strain echocardiography, left atrial dysfunc-
tion was identiﬁed in 32% (lateral left atrial criteria)
and 60% (septal left atrial criteria) of patients with
amyloidosis (12). Severe atrial and ventricular inﬁl-
tration by amyloid may result in mechanical atrial
standstill, with resultant thrombus formation (13).
These ﬁndings have been identiﬁed by cardiac mag-
netic resonance (CMR) imaging (14). CMR has also
been used to estimate cardiac amyloid burden by
quantiﬁcation of myocardial extracellular volume
fraction (15). In addition to heart failure, patients may
present with atrial arrhythmias or conduction system
disease. In patients who have ventricular thickening
without a history of hypertension or valvular disease,
an inﬁltrative cardiomyopathy should be considered
(16). Deposition of amyloid into the myocardial wall
causes diastolic dysfunction, restrictive physiology
with late loss of systolic function, arrhythmias, and
heart failure (17). The ﬁnding of increased wall
thickness, small ventricular volume, and occasional
dynamic left ventricular outﬂow tract obstruction can
be confused with true hypertrophic conditions such
as hypertrophic cardiomyopathy and hypertensive
heart disease. Although the electrocardiogram clas-
sically shows low voltage in the QRS complex in
amyloidosis and increased voltage in myocyte hy-
pertrophy disorders, the overlap is great; voltage can
be useful but is not reliable (18,19).
Clues to the presence of amyloid cardiomyopathy
are seen in the widespread deposition of amyloid. In
patients with wt ATTR, one-half have associated
carpal tunnel syndrome caused by deposition of TTR
amyloid into the carpal tenosynovial tissue, with
hand symptoms typically preceding cardiac manifes-
tations by 8 to 10 years. Of patients with idiopathic
carpal tunnel syndrome, 34% will have amyloid
deposition in tenosynovial tissue, possibly repre-
senting an early symptom of wt ATTR cardiomyopa-
thy (20).
Clinical presentation of mutant ATTR is variable
and driven by the speciﬁc mutation, of which w110
have been described. Patients with mutant ATTR
present on a spectrum from exclusive neuropathy to
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2453cardiomyopathy-overlapping phenotypes. Among 611
symptomatic patients with hereditary TTR, multi-
system involvement was seen with each mutation
(21). The quality of life in patients with hereditary
ATTR is severely impaired.
GENERAL CHARACTERISTICS
OF TTR AMYLOIDOSIS
In a study of ATTR cardiomyopathy, 212 of 266 pa-
tients were men (80%) (22), and in the Transthyretin
Amyloidosis Outcomes Survey data registry, 72% of
patients with mutant ATTR were male and 99% with
wt ATTR were male (21). The mean left ventricle wall
thickness was higher in wt ATTR than in mutant
ATTR, and mutant ATTR less often had low voltage in
the QRS complex (only 25% of patients). Mutant and
wt ATTR had a favorable survival rate compared with
that of AL amyloidosis and other forms of amyloid
cardiomyopathy (19).
A particularly important form of amyloid cardio-
myopathy caused by mutant TTR in the United States
is the V122I mutation, which has been identiﬁed in
124 of 3,856 (3.2%) of blacks (23) and should be
considered in black men >50 years of age with heart
failure symptoms and thickened ventricular walls
with echocardiography. Of interest, mortality rates
are not markedly different between V122I carriers and
noncarriers (23). However, the V122I variant is asso-
ciated with a 47% higher risk of incident heart failure,
worse systolic and diastolic cardiac function, and
signiﬁcantly higher levels of NT-proBNP compared
with noncarriers. V122I ATTR may be more benign
than previously thought. Nevertheless, even when
clinically apparent amyloidosis is absent, patients
with the V122I mutation have a higher incidence of
New York Heart Association functional class 3 and 4
heart failure (10%) (24).
Extracardiac symptoms provide an important
clinical clue when mutant ATTR is the cause of an
inﬁltrative cardiomyopathy. Among a cohort of pa-
tients with T60A (p.T80A) amyloidosis, 82% had
cardiomyopathy, but 65% also had peripheral neu-
ropathy (22). Among those with V30M amyloidosis
(the most commonly recognized mutation globally to
date), 43% have cardiomyopathy and 95% have pe-
ripheral neuropathy. Furthermore, even in V122I
amyloidosis, which causes cardiomyopathy for all
patients, we found that 30% also had peripheral nerve
symptoms that were generally mild but part of the
chief concern in 7%. When present, peripheral nerve
symptoms in a patient with cardiomyopathy may
suggest systemic amyloidosis (25). The ﬁnding of
peripheral neuropathy is suggestive of amyloidosis ina patient with: 1) heart failure with preserved ejection
fraction; or 2) imaging ﬁndings consistent with inﬁl-
trative cardiomyopathy. Patients with some forms of
mutant TTR amyloid also ultimately have renal
dysfunction; in a cohort of patients with V30M ATTR,
dialysis was initiated at an average of 10.2 years after
the onset of neuropathy (26). Dialysis-dependent
renal failure was preceded by nephrotic-range pro-
teinuria. When renal replacement therapy was initi-
ated, the 2-year treatment survival rate was only
38.4%.
The natural history of wt ATTR is much better than
other forms of amyloid cardiomyopathy (19). In 1 of
the ﬁrst studies, the median survival was 60 months
from presentation with heart failure symptoms,
whereas it was 5.4 months for patients with cardio-
myopathy from AL amyloidosis (27). Characteristics
of wt ATTR include greater left ventricular wall
thickness than that of patients with AL amyloidosis,
less-severe heart failure, and a median survival of 75
versus 11 months, again suggesting a more protracted
clinical course (28). Despite the long clinical course of
heart failure, the disease is progressive with time.
Echocardiography, 6-min walk, and NT-proBNP
revealed signiﬁcant declines in myocardial perfor-
mance over a 6-month observation period (29). In a
large series of more than 100 patients with wt ATTR,
median survival from onset of symptoms was 6.07
years. Predictors of shorter survival included troponin
elevation, the need for a pacemaker, and elevation
of New York Heart Association functional class (30).
All patients with amyloid peripheral or autonomic
neuropathy need screening for cardiac involvement.
Amyloid neuropathy is classically a symmetric,
ascending lengthdependent, sensorimotor, axonal
polyneuropathy. It is associated with a high incidence
of carpal tunnel syndrome and autonomic neuropa-
thy manifesting as orthostatic hypotension, sweat
abnormalities, urinary incontinence, erectile dys-
function, alternating diarrhea and constipation, and
orthostatic syncope. In a screening study of 81 pa-
tients with FAP due to V30M, 17% had severe thick-
ening of the intraventricular septum (>15 mm) (31).
The following clinical features are characteristic
of TTR FAP and are useful for distinguishing this
polyneuropathy from inherited and acquired poly-
neuropathies. First, TTR FAP is a symmetric, distal
polyneuropathy that typically begins in the lower
limbs, progresses to the upper limbs, and then
affects more proximal aspects of the limbs and
even the trunk. Second, it is an axonal poly-
neuropathy affecting all functional classes of nerve
ﬁbers (i.e., motor, sensory [large and small], and
autonomic ﬁbers), which can distinguish it from other
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2454inherited neuropathies, especially those predomi-
nantly involving small sensory nerve ﬁbers (heredi-
tary, sensory, and autonomic neuropathies) or
selectively involving large sensory ﬁbers (spinocer-
ebellar degenerations). Third, its onset typically be-
gins at the end of the second decade of life or later
and progresses substantially during the next 1 or 2
decades. Fourth, a family history of a similar poly-
neuropathy is usually present but often is notTRATION Evaluation to Diagnose ATTR
tient with suspected transthyretin amyloidosis (ATTR)
atients with heart failure with preserved ejection fraction)
Established diagnosis of ATTR
uation results suggestive of ATTR
sical exam
idence of autonomic neuropathy
immunoglobulin free LC assay 
rmal values (excludes LC amyloidosis)
e test
idence of nephrotic range proteinuria
ue and strain Doppler echocardiography
idence of left atrial dysfunction (lateral or septal)
idence of biventricular hypertrophy
iac magnetic resonance imaging
ionuclide imaging
cer uptake detects myocardial amyloid deposition
iac biomarkers
idence of troponin and brain natriuretic peptide 
ent history
idence of carpal tunnel syndrome
sy
, skin, salivary gland, or gastrointestinal tract
less-invasive biopsy is negative)
s spectroscopy (preferred) or immunohistochemical/
unogold staining with electron microscopy (less accurate)
idence of ATTR amyloid deposit type 
cludes LC amyloidosis)
 Am Coll Cardiol. 2015; 66(21):2451–66.
to arrive at a diagnosis of ATTR. ATTR ¼ transthyretin amyloidosis;recognized clinically because family histories are not
rigorously obtained. Fifth, concurrent involvement of
visceral organs (e.g., heart or kidneys) is common. A
high index of suspicion is required because amyloid
polyneuropathy is initially suspected in only 38% of
patients presenting with peripheral nerve symptoms
and no family history (32). The Central Illustration lists
the recommended diagnostic evaluation for patients
with suspected amyloidosis. The purpose of serum
immunoﬁxation and the immunoglobulin free light
chain assay is to exclude AL amyloidosis. Although an
echocardiogram or cardiac magnetic resonance (CMR)
imaging may suggest inﬁltrative cardiomyopathy,
these cardiac diagnostic tests cannot reliably predict
amyloid type. Absence of a monoclonal light chain
should not reduce the index of suspicion for
amyloidosis because ATTR is not associated with the
presence of a monoclonal protein.
PREVALENCE OF ATTR. Because of the wide geo-
graphic distribution of mutant ATTR and regional
differences in mutation rate, accurate statistics on the
prevalence of mutant ATTR are difﬁcult to obtain.
Relative frequencies, however, have been reported.
Among 100 patients seen at an amyloid referral center
who all had endomyocardial biopsy, 74 had AL
amyloidosis, 22 had wt ATTR, and 4 had mutant ATTR
(33). This study, conducted in the United States
(where the incidence of AL amyloidosis is 8 per
million/year) would translate to 0.4 per million/year
for mutant ATTR.
However, a recent review suggests that wt ATTR
may be under-recognized (34). Histologically, cardiac
vascular involvement is seen in 88% of patients with
AL cardiomyopathy and in only 26% with wt ATTR,
but the biopsy ﬁnding of cardiac amyloid with no
vascular involvement should heighten the suspicion
of ATTR. A study of cord blood from 1,000 children
born at a U.S. county hospital to mothers who self-
identiﬁed as black showed a 3% frequency of the
TTR mutation V122I (35), although its penetrance is
probably low. On the basis of a prospective French
study, the estimated prevalence gave an age-
standardized incidence rate of amyloidosis at 14
cases per million person-years, constituting 66 pa-
tients in 3 years (36). Of these patients, 60% had wt
ATTR and 20% had AL amyloidosis; no cases of
mutant ATTR were reported. The nature of data
collection makes the conclusions uncertain.
Autopsies suggest that the prevalence of wt ATTR
is much greater than previously reported. In 1 autopsy
study of people >85 years of age, wt ATTR was pre-
sent in 25% (37). The fraction of autopsied patients
with clinically signiﬁcant symptoms is not known. In
a consecutive series of surgical pathology specimens
FIGURE 1 Echocardiogram of a 62-Year-Old Man With Biopsy-Proven
Endomyocardial Amyloid
Laser capture mass spectroscopy showed transthyretin, and sequencing showed a
wild-type TTR gene. EDV ¼ end diastolic volume; IVSd ¼ interventricular septal thickness
diastole; IVS/LVPW ¼ interventricular septal thickness/left ventricular posterior wall
thickness; LVIDd ¼ left ventricular internal diameter diastole; LVPWd ¼ left ventricular
posterior wall diastole.
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2455with ATTR (n ¼ 33), mutant TTR was found in 36%
and wt TTR in 64%, emphasizing that wt TTR is more
common (38). Endomyocardial biopsies from 101 pa-
tients with amyloid showed AL in 54 and ATTR in
42 (39). Overall, 5 of 42 patients with ATTR had
mutant TTR.
Among patients presenting with peripheral neu-
ropathy, 6 of 16 (38%) had cardiac amyloidosis, as
evidenced by cardiac radiotracer uptake and by CMR,
emphasizing the need for cardiac screening in all pa-
tients with peripheral neuropathy due to amyloid,
even those without clinical signs of cardiac involve-
ment (40). The true prevalence of wt ATTR is unknown
because true population-based surveillance has never
been performed. In an autopsy study of 109 patients
with heart failure with preserved ejection fraction
(but not suspected of having amyloidosis) and 131
control subjects, amyloid deposits were found in
18 patients with heart failure with preserved ejec-
tion fraction (17%) and 7 control subjects (5%)
(32). The frequency increased with each decade of
life (from 70 to >90 years of age). Wt ATTR is an
increasingly recognized cause of heart failure with
preserved ejection fraction, and amyloidosis should
be considered in the differential diagnosis of this
increasingly recognized syndrome.
ECHOCARDIOGRAPHY. Echocardiography is the mo-
dality by which virtually all patients with cardiac
ATTR are recognized. The most common ﬁnding is
thickening of both the left ventricle free wall and the
septum (41) (Figure 1). This can be misdiagnosed as
hypertrophic cardiomyopathy or hypertensive car-
diomyopathy. Patients with an exclusively cardiac
phenotype (i.e., lacking neuropathy or autonomic
features) show more pronounced cardiac involve-
ment on echocardiography and electrocardiogram. In
a study of 13 patients, all with ATTR, echocardiogra-
phy showed biventricular hypertrophy, left atrial
enlargement, and normal to slightly reduced left
ventricular ejection fraction (42). Tissue Doppler
septal e was low, and median E/e was high. “E” and
“e” represent waves seen on tissue Doppler and
reﬂect early diastolic ﬁlling and mitral inﬂow; the
ratio E/e reﬂects diastolic compliance. Right-sided
catheterization showed the classic restrictive ﬁlling
pattern, with a median pulmonary wedge pressure of
21 mm Hg. Electrocardiograms with low-voltage QRS
complexes were seen in only 36%, pseudoinfarction
pattern with poor R-wave progression in 65%, and
atrial ﬁbrillation in 36% of patients. In a study of 48
patients with ATTR (29 with wt TTR, 19 with mutant
TTR), all patients met criteria for cardiac involvement
with a left ventricle thickness >12 mm (43). Patientswith ATTR had increased left and right ventricular
chamber volume, increased left and right ventricular
wall thickness, reduced left ventricular ejection
fraction, and fractional shortening. Despite this,
these patients had lower NT-proBNP levels than pa-
tients with AL amyloidosis. ATTR also appears to
have a slower progression than AL amyloidosis. When
echocardiograms from patients with AL amyloidosis
and ATTR (36 mutant, 56 wt) were compared, longi-
tudinal strain was severely impaired for both but was
worse in AL amyloidosis.
Compared with mutant ATTR, wt ATTR is charac-
terized by a greater left ventricular wall thickness,
greater depression of ejection fraction, and higher
longitudinal strain. Worsening left ventricle function
correlated with increasing wall thickness. Patients
with wt ATTR had greater wall thickness but a lower
mortality rate (19,44). Tissue and strain Doppler im-
aging are essential for detecting cardiac amyloidosis
because these techniques can detect early amyloid
myocardial involvement before it can be seen with
traditional echocardiography (45). A total of 55 pa-
tients with cardiac amyloidosis were compared with
30 control patients with left ventricular hypertrophy.
A relative apical longitudinal strain (LS) of 1.0
(deﬁned using the equation: Relative apical LS ¼
average apical LS/[average basal LS þ average mid
LS]) had 93% sensitivity and 82% speciﬁcity in
FIGURE 2 Cardiac
Thickening of the R
Free Wall
Amyloid inﬁltration c
Gertz et al. J A C C V O L . 6 6 , N O . 2 1 , 2 0 1 5
Diagnosis and Management of TTR Amyloid D E C E M B E R 1 , 2 0 1 5 : 2 4 5 1 – 6 6
2456differentiating patients with amyloidosis from con-
trol patients. Relative apical longitudinal strain was
the only parameter predictive of cardiac amyloidosis
(p ¼ 0.004) (46).
CMR IMAGING. CMR has enhanced the ability to
recognize cardiac amyloidosis (Figure 2) because it
shows a distinct pattern of late gadolinium enhance-
ment over the entire subendocardial circumference
(Figure 3). This pattern was found in 12 of 15 patients
with positive endomyocardial biopsy (47). The
sensitivity of CMR for cardiac amyloidosis was 80%
and the speciﬁcity was 94%, with a positive predic-
tive value of 92% and a negative predictive value of
85%. CMR is useful when distinguishing cardiac
amyloidosis from hypertrophic cardiomyopathy and
hypertensive heart disease. In 1 study, late gado-
linium enhancement was observed in 6 of 6 patients
with cardiac amyloid, and the number of enhancing
segments was signiﬁcantly greater in cardiac
amyloidosis (seen in 8 of 9) than in hypertrophic
cardiomyopathy or in hypertensive heart disease
(seen in 6 of 11) (48). In a prospective study of 53
patients with mutant ATTR and 14 asymptomatic
carriers, positive late gadolinium enhancement was
detected in 60% of patients but not in carriers (49).
A diffuse pattern of enhancement was seen exclu-
sively in patients with cardiac symptoms. Cardiac
amyloid on CMR was observed in 19% of patients withMagnetic Resonance Imaging Without Gadolinium Shows Dramatic
ight Ventricle, Interventricular Septum, and Left Ventricular
ausing wall thickening.isolated mutant ATTR neuropathy and 20% of
patients without wall thickening. An attempt was
made to use CMR to differentiate AL from ATTR in
patients with cardiac amyloidosis. With use of a
late gadolinium enhancement scoring system in
conjunction with age and wall thickness, ATTR was
identiﬁed with greater sensitivity (87%) and speci-
ﬁcity (96%) compared with AL (50). Moreover, CMR
was able to differentiate AL from cardiac ATTR. A
total of 90% of patients with ATTR demonstrated
transmural late gadolinium enhancement, compared
with 37% of patients with AL (50).
Native myocardial T1 mapping by CMR was studied
in 85 patients with ATTR amyloid (50 with wt TTR)
and 79 patients with AL amyloid. Native myocardial
T1 mapping detected early cardiac ATTR amyloid and
had similar performance characteristics for diag-
nosing and tracking disease in both ATTR and AL
amyloidosis (51).
Magnetic resonance imaging is also capable of
detecting lower-limb nerve injury and quantifying
nerve injury in vivo on a microstructural level. The
use of magnetic resonance imaging to assess FAP is
ongoing (52).
RADIONUCLIDE IMAGING OF CARDIAC AMYLOIDOSIS. The
utility of radionuclide imaging in recognizing cardiac
amyloidosis dates back over 30 years (53). Ten years
ago, in an attempt to differentiate AL amyloidosis
from ATTR, the diagnostic accuracy of 99mTechne-
tium (Tc)–3,3-diphosphono-1,2-propanodicarboxylic
acid (DPD) was investigated (54). Using echocardi-
ography as the reference standard for cardiac
involvement, sensitivity and speciﬁcity were 100%
for ATTR, and DPD was proposed as a useful diag-
nostic component for distinguishing between forms
of cardiac amyloidosis (Figure 4). However, the same
group later reported that although 99mTc-DPD scin-
tigraphy could be useful for differentiating ATTR
from AL amyloidosis–related cardiomyopathy, its
diagnostic accuracy was lower than previously re-
ported because of a mild degree of tracer uptake in
about one-third of patients with AL amyloidosis (55).
Another publication from the same group reported
that 99mTc-DPD showed tracer uptake in all 63 pa-
tients with ATTR, 23 of whom did not have echocar-
diographic evidence of inﬁltrative cardiomyopathy,
indicating the ability of this tracer to diagnose cardiac
involvement early in the disease course, before the
appearance of echocardiographic abnormalities
(56). 99mTc-DPD has been compared with CMR for
assessing cardiac involvement. Both techniques
have similar capabilities for identifying myocardial
amyloid deposition, but the inﬁltration burden can
FIGURE 3 Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging
Arrow indicates myocardial nulling.
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2457be markedly underestimated by visual analysis of
CMR compared with 99mTc-DPD (57).
99mTc-pyrophosphate also has been used as a car-
diac tracer and was reported to be equally efﬁcacious
in both mutant and wt ATTR (58). Further investiga-
tion of 99mTc-pyrophosphate showed 97% sensitivity
and 100% speciﬁcity for identifying cardiac ATTR. In
the United States, 99mTc-pyrophosphate is more
easily obtained than the DPD tracer (59). In a review,
the sensitivity and speciﬁcity of the 99mTc-DPD and
99mTc-pyrophosphate tracers appeared comparable
(60). A new tracer, 99mTc–hydroxymethylene di-
phosphonate, can detect ATTR amyloid before echo-
cardiographic evidence of cardiac involvement (61).
Subclinical cardiac involvement has also been
detected with the tracer when CMR and echocardi-
ography were nondiagnostic (62). Quantiﬁcation of
tracer retention of 99mTc-DPD can be used to charac-
terize the severity of cardiac involvement by ATTR,
although echocardiography remains the standard
(63). Radionuclide scanning with Tc-pyrophosphate
or 99mTc-DPD can heighten the suspicion of TTR car-
diac amyloidosis. A negative result can exclude car-
diac involvement or suggest that cardiac amyloid may
not be of TTR origin.
CARDIAC BIOMARKERS. Both troponin and B-type
natriuretic peptide are important cardiac biomarkers
for assessing the severity of cardiac amyloidosis.
Although initially used to study AL amyloidosis,
they were recently applied to detect cardiomyopa-
thy in ATTR. Among 29 patients who were evalu-
ated, troponin T was detectable in only 3 and
troponin I was detectable in 6, suggesting that TTR
amyloid is less toxic to myocytes than AL amyloid
(64). This ﬁts with the ﬁnding that, although cardiac
function declines as the ventricular wall thickens,
patients with wt TTR tolerate much greater degrees
of wall thickening and strain abnormality than pa-
tients with AL cardiac amyloidosis. This is consis-
tent with a hypothesis of additional toxicity by
soluble light chains in AL (44). B-type natriuretic
peptide was elevated in 76% of patients and corre-
lated signiﬁcantly with septal thickness and basal
septal strain; it appears to be a more sensitive
marker for familial amyloid cardiomyopathy. In an
evaluation of NT-proBNP in ATTR, the biomarker
correlated with left ventricular mass (calculated by
CMR) and with late gadolinium enhancement, sug-
gesting the utility of this biomarker as a measure of
cardiac amyloidosis severity (65). In a study of 36
carriers of mutant TTR (either asymptomatic or with
only neuropathy symptoms), NT-proBNP had 92%
sensitivity and 90% speciﬁcity for predicting echo-
cardiographic left ventricle abnormalities (66). Incarriers without cardiac symptoms or in patients
with only neurological symptoms, NT-proBNP can be
used to identify the best time to begin echocardio-
graphic assessment.
In another study, 13 patients with wt ATTR showed
signiﬁcant correlations between the log of B-type
natriuretic peptide and left ventricle wall thickness
(67). Although the data are limited, B-type natriuretic
peptide level is likely a useful prognostic marker of
cardiac function in wt ATTR.
DIAGNOSIS AND CLASSIFICATION
When treating a patient with evidence of inﬁltrative
cardiomyopathy consistent with amyloidosis, biopsy
veriﬁcation is essential. However, endomyocardial
biopsy (Figure 5) often is not necessary, particularly in
the elderly or in patients debilitated by neuropathy.
Noncardiac biopsies frequently will show amyloid
deposits in patients with echocardiography or CMR
ﬁndings consistent with amyloidosis, although posi-
tive noncardiac biopsies generally are less common in
ATTR than in AL amyloidosis. Surgical skin biopsy
can be performed safely at the bedside, with 1 study
reporting 11 patients with wt ATTR undergoing
FIGURE 4 Bone Scan Demonstrating TTR Amyloid in the Heart
(A) 99mTechnetinum (Tc)-3,3-diphosphono-1,2-propanodicarboxylic acid imaging of
wild-type transthyretin amyloid. The 64-year-old man had a score 3 uptake of the tracer.
(B) 99mTc–pyrophosphate with single-photon emission computed tomography imaging.
Courtesy of Geoffrey B. Johnson, MD, PhD, Mayo Clinic, Rochester, Minnesota
(used with permission).
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TTR amyloid deposits (sensitivity, 73%) (68). In a
retrospective review of 186 patients with mutant
ATTR and 100 patients with wt ATTR (69), 210 pa-
tients (73%) were positively identiﬁed after noncar-
diac tissue sampling, including 94% with mutant
ATTR and 35% with wt ATTR. Subcutaneous fat was
positive in 67% of patients with mutant ATTR
(Figure 6) and only 14% with wt ATTR. This indicatesthat a negative biopsy of an unaffected organ does
not exclude a diagnosis of ATTR, and in wt TTR, most
patients will require an endomyocardial biopsy to
establish the diagnosis. Bone marrow biopsy was
positive in 41% and 30% of patients with mutant and
wt TTR, respectively. Rectal and sural nerve biopsies
were positive in 81% and 83% of patients with mutant
and wt ATTR, respectively. Only 4 rectal biopsies
were performed among 100 patients with wt TTR; 2
were positive. Biopsy of minor salivary glands is used
in many centers, with a reported sensitivity of 61%
(70). Nerve biopsy should be reserved for patients
with symptomatic peripheral neuropathy. In an au-
topsy study of 6 subjects with wt ATTR and 5 with
mutant ATTR, 44% had positive amyloid deposits
from the gastrointestinal tract and subcutaneous tis-
sues (71). Noncardiac biopsy or fat aspiration could be
considered an initial diagnostic test to conﬁrm ATTR,
but it is important to remember that abdominal fat is
negative for most patients with wt TTR.
A diagnosis of wt TTR cardiac amyloidosis is
plausible in a patient with classic echocardiographic
features of amyloid cardiomyopathy, a technetium
scan that shows strong uptake, and sequencing that
shows no mutations in the TTR gene. Although these
ﬁndings are considered consistent with wt ATTR,
none of the actively enrolling trials currently accept
patients without histological conﬁrmation of
amyloidosis for wt ATTR. Some will enroll patients
with mutant ATTR if they have the classic presenta-
tion phenotype of cardiomyopathy or peripheral
neuropathy and a proven TTR pathogenic mutation.
In general, histological conﬁrmation of the amyloid is
strongly encouraged, even for patients with known
TTR mutations.
After amyloid is detected in tissue, correct classi-
ﬁcation of the type of amyloid protein is critical.
Historically, immunostaining with immunoperox-
idase or immunogold was used to conﬁrm ATTR, but
false positives can occur. In a study of 24 endomyo-
cardial biopsies for amyloid (72), 8 showed strong TTR
staining of cardiac amyloid deposits. Mass spec-
troscopy, considered the criterion standard for clas-
siﬁcation, was performed in 5, with all showing
light-chain amyloid protein. Among 15 patients with
plasma cell dyscrasias, 7 biopsies showed strong
staining for the corresponding monoclonal light
chains, and 8 were equivocal. Strong false-positive
immunostaining for TTR and cardiac amyloid is a
signiﬁcant pitfall, particularly when AL amyloid
frequently fails to stain because of deletion or mis-
folding of the epitopes (which makes them un-
recognizable by commercial antisera). In 142
consecutive biopsy specimens from 38 different
FIGURE 5 Endomyocardial Biopsy Shows Amyloid
Sulfated Alcian blue; original magniﬁcation  1,000.
FIGURE 6 Fat Aspirate Viewed Under Polarized Light
Congo red; original magniﬁcation  1,000.
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100% concordant with mass spectroscopy ﬁndings.
Mass spectroscopy improved the diagnostic accuracy
from 76% to 94% (73). Amyloid type should be
conﬁrmed with mass spectroscopy.
In a study of 117 patients with amyloid (74),
immunohistochemical analysis had a sensitivity of
96% and speciﬁcity of 100% for identifying inherited
amyloidoses. Immunohistochemistry allowed deﬁnite
classiﬁcation of 92% of patients, and mass spectros-
copy was used to classify inconclusive cases. In a large
study of 423 cases with conﬁrmed systemic amyloid-
osis (75), immunoelectron microscopy of abdominal
fat showed 80% sensitivity and 100% speciﬁcity.
However, the analysis of abdominal aspirate was
informative in only 40% of patients with ATTR.
Mass spectroscopic proteome analysis is applicable
to amyloid in a subcutaneous fat aspirate. Among 366
analyses, the sensitivity of the assay was 88% and the
speciﬁcity was 96%; this analysis identiﬁed all forms
of amyloid, including immunoglobulin light chain in
74%, TTR in 13%, and others in 3% (76). A universal
amyloid proteome signature has been identiﬁed, and
databases have been created to detect amyloidogenic
peptides. Although not widely available globally,
mass spectroscopic conﬁrmation of the type of amy-
loid is strongly recommended. The Central Illustration
presents the diagnostic evaluation for a patient with
an established diagnosis of amyloidosis.
THERAPY
SUPPORTIVE CARE. Although diuretic agents are
commonly prescribed for patients with heart failure,
their use in amyloidosis is complicated. As a conse-
quence of poor ventricular compliance, end-diastolic
volumes are low. Patients often require a higher
ﬁlling pressure to distend the stiffened heart, and
diuretic therapy reduces preload, which can further
reduce stroke volume and systolic blood pressure,
with resultant cerebral hypoperfusion. Diuretic
agents must therefore be used with care. Beta-
blockers, angiotensin-converting enzyme inhibitors,
and angiotensin receptor blockers are poorly tolerated
in cardiac amyloidosis and should be avoided (77).
Digoxin binds to amyloid ﬁbrils and can lead to locally
high levels; it also must be used with caution (78,79).
CARDIAC DEVICES. Death in cardiac amyloidosis can
result from progressive pump failure and is hemo-
dynamically characterized by high ﬁlling pressures
and low cardiac output. Right atrial pressure, pul-
monary artery diastolic pressure, pulmonary capillary
wedge pressure, and pulmonary artery saturationare predictors of death (80). Sudden death from
bradyarrhythmia and electrical mechanical dissocia-
tion is a competing cause of cardiac death. Given
the high incidence of sudden death in patients
with TTR cardiac amyloidosis, considering prophy-
lactic placement of an implantable cardioverter-
deﬁbrillator is rational. In 1 study, 19 patients
with cardiac amyloidosis and a history of syncope
or ventricular extrasystoles had an implantable
cardioverter-deﬁbrillator placed (81). Seven patients
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cardia, as recorded in pacing, was rare. Better pre-
dictors of arrhythmia-associated sudden cardiac
death are required to truly understand the effect of
an implantable cardioverter-deﬁbrillator in cardiac
amyloidosis. We reported the placement of implant-
able cardioverter-deﬁbrillators in 9 patients with
mutant ATTR and 10 with wt ATTR (82). The rate of
appropriate implantable cardioverter-deﬁbrillator
shocks was 32% in the ﬁrst year, observed almost
exclusively in patients with AL amyloidosis. Only 2
with wt TTR and none with mutant ATTR received
appropriate implantable cardioverter-deﬁbrillator
shocks. Device placement did not translate into an
overall survival beneﬁt. Early insertion of a pace-
maker can be helpful because bradyarrhythmia, when
it occurs, causes severe symptoms, and implantable
cardioverter-deﬁbrillators have increased rates of
complications. An implantable device for primary
prevention was reported in 4 patients with wt TTR
and 3 with mutant TTR. Four of these were de-
ﬁbrillators, and in 1 patient, a shock was aborted
because of spontaneous termination. This patient
survived at least 23 months (83). One concern about
failure of an implantable deﬁbrillator to rescue
amyloidosis patients is a higher deﬁbrillation
threshold. A subcutaneous array lead system can
reduce this threshold and result in successful deﬁ-
brillation (84).
Selection criteria were published for patients with
familial amyloidosis who would beneﬁt from pro-
phylactic pacemaker placement. A His-ventricular
interval $70 ms, His-ventricular interval >55 ms
when fascicular block is present, or Wenckebach
anterograde point #100 beats/min were considered
for prophylactic implantation. Follow-up of these
patients documented a high-degree atrioventricular
block in 25% (85).
Left ventricular assist devices have been implanted
in patients with TTR cardiac amyloidosis. Among
9 patients with the device, 2 died before hospital
discharge, 3 died after discharge (median survival 13.7
months), and the remaining 4 survived with 16 to 24
months of follow-up (86). Gastrointestinal bleeding
was seen in 3 of the 9. Implantation of a left ven-
tricular assist device is feasible, but its exact role in
ATTR currently is undeﬁned. A study of left ventric-
ular assist devices in 28 patients with restrictive car-
diomyopathy included 10 patients with amyloidosis
(87). The 1-year survival for patients who did not
undergo heart transplantation was 64% and was not
signiﬁcantly affected by amyloidosis status. The most
common complication was right ventricular failure.
Smaller left ventricle dimensions may represent anadvanced stage of the cardiomyopathy process that is
less responsive to assist device support. Alterna-
tively, smaller left ventricle dimensions present
technical challenges for left ventricular assist device
inﬂow cannula implantation and may result in sub-
optimal device placement and inadequate mechanical
support.
LIVER TRANSPLANTATION. Liver transplantation
has been considered the ﬁrst-line therapeutic inter-
vention for patients with mutant ATTR. Because the
bulk of TTR is produced in the liver, replacing mutant
TTR production with wt TTR was initially postulated
to stop the progression of amyloidosis. However,
limitations to the value of liver transplant have been
identiﬁed. Wt TTR deposits in the heart, kidneys,
peripheral nerves, and gastrointestinal tract have
been identiﬁed in autopsied patients with mutant
ATTR polyneuropathy who did not undergo liver
transplantation. The proportion of wt versus mutant
TTR in deposits and age at death are signiﬁcantly
correlated. The presence of wt and mutant TTR
codeposits in the heart can be a major impediment to
the long-term success of liver transplantation (88).
Over a decade ago, patients with mutant TTR poly-
neuropathy were noted to have codeposits of mutant
and wt TTR in nerves and in the heart (60% mutant,
40% wt) (89). Deposition of wt TTR on a mutant TTR
substratum can result in progression of cardiac
amyloidosis after liver transplantation. In an autopsy
study (90), patients without a liver transplantation
showed 60% mutant TTR and 40% wt TTR, but pa-
tients who underwent liver transplantation had a
mutant to wt TTR ratio of 25:75, suggesting continued
deposition of wt TTR in cardiac tissue after liver
transplantation.
Ongoing deposition of wt TTR affects health-related
quality of life after liver transplantation. Studies have
shown that quality of life is stable in the ﬁrst 4 years
after transplantation, but physical well-being after
4 years was signiﬁcantly lower compared with non-
ATTR liver transplant recipients (91). Patients with
the longest follow-up had deterioration in all health
domains. Low health-related quality of life after liver
transplantation is an ongoing issue in patients with
mutant ATTR. Deposition of wt TTR after liver trans-
plantation appears to be time-dependent, with a
higher proportion of wt TTR at 1 year compared with
3 weeks; furthermore, the deposited protein is full-
length TTR, not TTR fragments (92). Among 10 pa-
tients with mutant TTR receiving a liver transplant in
Spain, 4 subsequently died (on post-transplant days 3,
510, 730, and 2,290) (93). Patients who underwent
combined heart and liver transplant had better sur-
vival than those with heart transplantation alone. This
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with liver transplantation, removes the nidus of
mutant TTR (upon which wt TTR codeposits) and
prolongs survival.
After liver transplantation, peripheral neuropathy
can progress, just as cardiac amyloidosis progresses.
However, current pathophysiological understanding
of speciﬁc mechanisms is limited by clinical com-
plexity (i.e., neuropathy can be caused by numerous
factors, such as neurotoxic immunosuppression,
post-transplant hyperinsulinemia, and other disease
entities). In 1 study, a subject who died 5 years after
liver transplantation had a nerve containing 75% wt
TTR, which was associated with clinical symptoms
of progressive neuropathy (94). Serial echocardio-
graphic monitoring of patients with V30M ATTR af-
ter liver transplantation showed markedly increasing
interventricular septal thickness with time, presum-
ably due to cardiac deposition of wt TTR (95). Re-
sults after liver transplantation appear to be
mutation-dependent, with the V30M mutation be-
ing associated with the most favorable outcomes. At
many centers, patients with non-V30M ATTR are not
commonly offered liver transplantation as an option
(96). With long-term follow-up (>10 years) after liver
transplantation, wt TTR deposits are seen in the
heart, tongue, and spinal cord (97). Clinical
involvement of the central nervous system appears
to occur in V30M ATTR, regardless of liver trans-
plantation; 31% of patients with V30M ATTR
had clinical manifestations of focal neurological
episodes (98).
Altogether, long-term outcomes of liver trans-
plantation for mutant ATTR indicate that neuropathy
and organ impairment are not usually reversed. Five-
year survival rates in 1 study (99) were 100% and 59%
for V30M and non-V30M ATTR, respectively, with
death primarily caused by cardiac problems and
sepsis. Lower survival is associated with malnutri-
tion, disease duration, and older age at diagnosis (99).
A recent analysis of the Familial Amyloidotic Poly-
neuropathy World Transplant Registry (n ¼ 1,940)
reported an overall 20-year survival rate after liver
transplantation of 55.3% (100). Multivariate analysis
showed modiﬁed body mass index, early onset of
disease (age <50 years), disease duration before
transplantation, and TTR V30M versus non-V30M
TTR mutations as independent, signiﬁcant factors
affecting survival. In this large study, 5-year survival
was 80%, and 10-year survival ranged from a low of
28% in men >50 years of age with V30M to 78% for
men <50 years of age with V30M (100).
Combined cardiac and liver transplantation has
been reported. In a series of 25 patients with ATTR,18 of whom showed end-stage heart failure (101),
5 patients (age 43 to 57 years) had cardiac trans-
plantation, with 1 having a subsequent liver trans-
plant. A total of 3 were listed for liver transplantation,
and 1 patient showed recurrent cardiac amyloid by
electron microscopy only. In the short term, com-
bined cardiac and liver transplantation is feasible. In
1 report, 7 patients received combined heart and liver
transplantation for TTR amyloid cardiomyopathy
(102). Two died within the ﬁrst year. Five patients, all
carrying an L111M (p.L131M) mutation, survived with
normal ejection fraction and no recurrence of cardiac
amyloid. These results are encouraging. Cardiac
transplantation to restore normal function, followed
by liver transplantation to prevent recurrent amyloid
deposition, is feasible in younger patients with
mutant TTR cardiac amyloidosis.
Isolated heart transplantation has also been per-
formed. It may be particularly beneﬁcial for the pa-
tients with the V122I TTR mutation, which has late
onset and often does not deposit outside of the heart.
In a case report, no systemic abnormalities were
detected 5 years after heart transplantation (103). A
second patient with V122I ATTR was well 3 years later,
without systemic amyloid deposition (104). A case
series of 10 patients (2 withwt TTR, 7 withmutant TTR,
and 1 unknown) undergoing cardiac transplantation
reported only 1 episode of amyloid in the cardiac graft,
suggesting that in the short to intermediate term,
isolated cardiac transplantation is feasible (105).
PHARMACOLOGICAL THERAPY OF ATTR. Consider-
ing the limitations of liver transplantation, the age at
which many patients are diagnosed, and the lack of
donor organs, pharmacological agents are needed
(106). Techniques have been developed that serially
assess patients with familial amyloid neuropathy to
measure the rate of regression or progression of
neuropathic symptoms (107). Table 2 lists some agents
currently being investigated in registered clinical tri-
als (106).
In vitro studies suggest that epigallocatechin
gallate, the most abundant catechin in green tea, in-
hibits amyloid ﬁbril formation of several amyloido-
genic proteins. One study described 19 patients with
ATTR cardiomyopathy who were serially evaluated
with echocardiography and CMR after consuming
green tea or green tea extracts (108). After 12 months,
no increase in left ventricular wall thickness or left
ventricular mass was observed by echocardiography,
suggesting that green tea or its extracts might inhibit
progression of cardiac amyloid.
In 2006, orally administered diﬂunisal was reported
to stabilize the TTR tetramer against association with
amyloidogenic monomers (109). Diﬂunisal can bind
TABLE 2 Selected Trials for TTR Amyloidosis
Drug Phase TTR Type Organs Study Number
Doxycycline þ
tauroursodeoxycholic acid
II Wild type and
mutant
Cardiac,
nerve
NCT01171859
Revusiran (ALN-TTRsc), Alnylam
Pharmaceuticals Cambridge
(Cambridge, Massachusetts)
III Mutant Cardiac NCT02319005
Tafamidis III Wild type and
mutant
Cardiac NCT01994889
Diﬂunisal II/III Mutant Nerve NCT01432587
Patisiran (ALN-TTR02),
Alnylam Pharmaceuticals Cambridge
(Cambridge, Massachusetts)
III Mutant Nerve NCT01960348
ISIS-TTRRx Isis Pharmaceuticals
(Carlsbad, California)
III Mutant Nerve NCT01737398
SOM0226, SOM Biotech SL
(Barcelona, Spain)
I-II Mutant Nerve NCT02191826
TTR ¼ transthyretin.
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increasing the tetramer dissociation barrier and stabi-
lizing the tetramer from forming monomers that mis-
fold into the amyloid conﬁguration (110). This phase I
trial supported the safety of diﬂunisal administration,
with kinetic studies showing binding to TTR and
slowing of urea-mediated dissociation, setting the
stage for future clinical trials (109).
Diﬂunisal was shown to be safe for patients with
compensated cardiac ATTR (111). A randomized clin-
ical trial reported in 2013 showed reduced progression
of neurological impairment and preserved quality
of life 2 years after randomization to therapy with
diﬂunisal; however, no information was provided
regarding the cardiac response (112). Diﬂunisal may
also be effective for autonomic dysfunction and late-
onset FAP caused by V30M ATTR (113). Because
diﬂunisal is a nonsteroidal anti-inﬂammatory drug,
potential adverse effects must be considered. Many
patients with ATTR are taking diﬂunisal on the basis
of these reports.
Tafamidis has been approved in the European
Union and in Japan for treatment of mutant ATTR. It
can produce kinetic stabilization to prevent TTR
amyloidogenesis, preventing dissociation of the
native TTR quaternary structure (114). Tafamidis
binds to the thyroxine-binding sites of the TTR
tetramer and inhibits its dissociation, thereby block-
ing the rate-limiting step of the TTR amyloid cascade.
In a randomized, double-blind trial, tafamidis signif-
icantly reduced neurological decline in most variables
examined, supporting the hypothesis that prevention
of TTR dissociation can delay peripheral neurological
impairment (115). Analysis of the open-label exten-
sion of this study showed that long-term treatmentwith tafamidis was well tolerated, with the reduced
rate of neurological deterioration sustained over 30
months (116). In a cohort of patients with non-V30M
ATTR, patients treated with tafamidis (20 mg/day)
did not show clinically relevant worsening of health-
related quality of life, NT-proBNP, or echocardio-
graphic parameters (117). In a post-approval trial by
the French Network for FAP, neurological impairment
scores worsened in 55% after 1 year of tafamidis
treatment, suggesting that it could not stop disease
progression (in terms of neural impairment) or
disability in patients with advanced disease (118). A
review of tafamidis (119) suggested that slowing
deterioration of neurological function beneﬁted
health-related quality of life in long-term extension
studies (up to 66 months). Tafamidis was capable of
stabilizing TTR tetramers in patients with non-V30M
ATTR and was well tolerated, with few patients dis-
continuing treatment. Currently, tafamidis is not
approved for use in the United States, but trials are
underway and are actively accruing patients (Table 2).
Tafamidis also prevents biochemical and echocar-
diographic decline in TTR cardiomyopathy (120).
Ten years ago, studies showed that small inter-
fering ribonucleic acid (siRNA) could selectively
silence V30M TTR gene expression in cell culture
systems (121). Advances in siRNA delivery and target
selection provided the opportunity to initiate human
trials using this technology (122). RNAi technology
has been harnessed to knock down the disease-
causing TTR protein, which is synthesized primarily
in the liver. Data from a mouse model showed that
the degree of TTR knockdown correlated with de-
creasing TTR tissue deposits. Patisiran (Alnylam
Pharmaceuticals Cambridge, Cambridge, Massachu-
setts), an investigational drug, uses a TTR-targeting
siRNA that knocks down both wt and all mutant
forms of TTR. The drug is encapsulated in lipid
nanoparticles, is administered through intravenous
infusion, and targets the liver. It was studied in a
single-dose, placebo-controlled, phase I trial in 32
ATTR patients and 17 healthy volunteers (123). At
doses of 0.15 to 0.3 mg/kg, mean reductions in TTR
ranged from 82.3% to 86.8%; at 28 days, reductions
ranged from 56.6% to 67.1%. This siRNA suppressed
mutant and wt TTR production, establishing proof-of-
concept for currently accruing phase III trials
(APOLLO). The trial is placebo controlled, and dura-
tion of therapy is 15 months. The primary endpoint is
change from baseline of modiﬁed Neuropathy
Impairment Score þ7. Initial results from a pilot,
phase 2 study of Revusiran (ALN-TTRsc) (Alnylam
Pharmaceuticals Cambridge), an investigational RNAi
therapeutic for cardiac ATTR, show that it was
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cant disease.
In addition to technologies investigating siRNA,
antisense oligonucleotide drugs have been developed
that inhibit hepatic expression of TTR. Antisense oli-
gonucleotides are deoxyribonucleic acid– or ribonu-
cleic acid–like molecules consisting of a short string of
nucleotides. For TTR, an antisense oligonucleotide
that is exactly complementary to the messenger
ribonucleic acid (mRNA) molecule that encodes TTR is
used. After the drug binds the mRNA, protein pro-
duction may be inhibited by ribonuclease H–mediated
destruction of the mRNA. Thus, the antisense drug
can prevent or dramatically decrease TTR production.
A transgenic mouse model with human TTR I84S
suppressed TTR levels by as much as 80% (124). In
phase I studies, the safety proﬁle was favorable, and
the agent produced dose-dependent reductions in
circulating TTR levels. In healthy volunteers, ISIS-
TTRRx (Isis Pharmaceuticals, Carlsbad, California)
produced rapid, dose-dependent reductions (approx-
imately 75%) in plasma TTR, although some subjects
had an approximate 90% reduction (125). Placebo-
controlled phase III trials are underway for amyloid
neuropathy (Table 2). Therapy is administered sub-
cutaneously once a week. The primary endpoint is
efﬁcacy of ISIS-TTRRx, as measured by change from
baseline in the modiﬁed Neuropathy Impairment
Score þ7 and change from baseline in the Norfolk
Quality of Life Diabetic Neuropathy questionnaire.
The trial runs for 64 weeks.
Doxycycline can disrupt ﬁbrils (126), and doxycy-
cline treatment of a mouse model of amyloidosis
resulted in amyloid disaggregation and improve-
ment in some tissue markers associated with TTR
deposition (127). Importantly, when doxycycline was
administered in combination with the antiapoptotic
agent tauroursodeoxycholic acid, a more pronounced,
synergistic effect on removal of tissue TTR deposits
was observed, paralleled by complete normalization
of known FAP tissue markers. On the basis of these
pre-clinical studies, a phase II, open-label study was
designed to evaluate the efﬁcacy, tolerability, safety,and pharmacokinetics of doxycycline (100 mg, twice
daily, orally) and tauroursodeoxycholic acid (250 mg,
3 times/day, orally) administered continuously for
12 months. Preliminary data support a beneﬁcial effect
with an acceptable toxicity proﬁle (128).
Administration of antihuman antibodies against
serum amyloid P component to mice with amyloid
deposits containing human serum amyloid P com-
ponent triggers a reaction that removes amyloid
deposits. Antibody treatment is feasible because cir-
culating human serum amyloid P component can be
depleted in patients by the bis-d-proline compound
CPHPC, thereby enabling injected antibodies to reach
residual serum amyloid P component in the amyloid
deposits (129).
SUMMARY
ATTR is easily confused with other forms of
inﬁltrative and hypertrophic cardiomyopathy. The
coexistence of systemic symptoms involving the
peripheral or autonomic nervous system and cardiac
dysfunction are important clues. Diagnosis of
mutant TTR is often established without an endo-
myocardial biopsy. A positive noncardiac biopsy is
much less likely in wt TTR compared with mutant
TTR. If typical echocardiographic or CMR ﬁndings
are present, a DPD or pyrophosphate nuclear scan of
the heart can establish the diagnosis of ATTR,
although current clinical trials require tissue conﬁr-
mation. Establishing the diagnosis early is relevant
because therapeutic interventions exist; treatments
include liver transplantation and newly developed
pharmacological agents that can stabilize the
tetramer, prevent misfolding, or block hepatic syn-
thesis of TTR. The standardized evaluation of
patients with this disorder (Central Illustration) can
be used to guide clinicians.
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